Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)

China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among topicalrefractory and moderatetosevere patients. Branded options are increasingly gaining momentum, with market growth driven by the uptake of IL-13 / IL-4 inhibitors, such as dupilumab (Sanofi’s Dupixent), and stapokibart (Keymed Biosciences’ Kangyueda), alongside oral JAK inhibitors, including abrocitinib (Pfizer’s Cibinqo), upadacitinib (AbbVie’s Rinvoq), and ivarmacitinib (Hengrui’s Aisuda) for moderate to severe AD. For mild to moderate disease, crisaborole and benvitimod provide nonsteroidal topical options and is supported by approval in patients aged 2 years and older. Emerging therapiesnew IL4 / IL13 inhibitors, oral JAK / TYK2 inhibitors, IL-13 inhibitors, OX40L inhibitors, and topical JAK and PDE-4 agentsare expected to broaden treatment choice across severity levels. In this report, we explore how unmet needs, pricing, coverage, regulatory reforms, NRDL, and VBP developments may influence access and uptake in China, which will influence the launch and uptake of new therapies in this highly lucrative market.

Questions answered

• What is the diagnosed prevalence of AD in China, and how are AD patients treated today?
• What are the key unmet needs in the management of AD?
• Who will be the leading player in the AD market by 2035?
• How will the AD therapy market evolve over the next 10 years??
• What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?

Product description

China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy in China.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
• Gauge the commercial outlook and impact of key market events.